On July 28, Regeneron Pharmaceuticals rose 3.05% in regular trading, trading at 690.075 USD/share, with turnover of $98.52 million. The gain came amid a broad rally across the biotechnology sector, with peers including Amgen up 5.28%, AbbVie up 3.33%, Gilead Sciences up 3.29%, and Alnylam Pharmaceuticals up 2.8%, reflecting significant capital inflows into the sector.

Additionally, the company is scheduled to report second-quarter earnings on July 30 before the market opens, with consensus EPS expectations of $8.0. Market participants may be adjusting positions ahead of the report. Notably, the company previously disclosed in an SEC filing that it expects Q2 GAAP and non-GAAP diluted EPS to decrease by approximately $1, which could factor into investor expectations surrounding the release.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)